CD79A and glioblastoma: According to the follow-up results, we think patients with anti-GBM disease combined with IgA deposition in the mesangial region may achieve good alleviating proteinuria at the early stage of treatment, while patients with classical anti-GBM disease still have proteinuria progression at the early stage of treatment.